Newly approved medication for Multiple Sclerosis

A 12 month study to compare the safety and efficacy of 2 doses of fingolimod every day vs. Copaxone 20mg SC every day for Relapsing Remitting MS.

  • Ages 18-65
  • Must have 1 documented relapse in the last year
  • No varicella zoster
  • No one with heart rate less than 45/bpm
  • No uncontrolled diabetes
  • No positive Hepatitis A, B, C and E